TWI654975B - 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎抗腫瘤用途 - Google Patents

卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎抗腫瘤用途 Download PDF

Info

Publication number
TWI654975B
TWI654975B TW104143630A TW104143630A TWI654975B TW I654975 B TWI654975 B TW I654975B TW 104143630 A TW104143630 A TW 104143630A TW 104143630 A TW104143630 A TW 104143630A TW I654975 B TWI654975 B TW I654975B
Authority
TW
Taiwan
Prior art keywords
patient
treatment
compound
prostate cancer
cabalitasol
Prior art date
Application number
TW104143630A
Other languages
English (en)
Chinese (zh)
Other versions
TW201611831A (en
Inventor
桑尼爾 古普達
Sunil Gupta
Original Assignee
安萬特醫藥公司
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI654975(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 安萬特醫藥公司, Aventis Pharma S.A. filed Critical 安萬特醫藥公司
Publication of TW201611831A publication Critical patent/TW201611831A/zh
Application granted granted Critical
Publication of TWI654975B publication Critical patent/TWI654975B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
TW104143630A 2009-10-29 2010-10-29 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎抗腫瘤用途 TWI654975B (zh)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US25616009P 2009-10-29 2009-10-29
US61/256,160 2009-10-29
US29390310P 2010-01-11 2010-01-11
US61/293,903 2010-01-11
US35583410P 2010-06-17 2010-06-17
US35588810P 2010-06-17 2010-06-17
US61/355,834 2010-06-17
US61/355,888 2010-06-17
US36992910P 2010-08-02 2010-08-02
US61/369,929 2010-08-02
US38393310P 2010-09-17 2010-09-17
US61/383,933 2010-09-17
US38996910P 2010-10-05 2010-10-05
US61/389,969 2010-10-05

Publications (2)

Publication Number Publication Date
TW201611831A TW201611831A (en) 2016-04-01
TWI654975B true TWI654975B (zh) 2019-04-01

Family

ID=43567614

Family Applications (2)

Application Number Title Priority Date Filing Date
TW104143630A TWI654975B (zh) 2009-10-29 2010-10-29 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎抗腫瘤用途
TW099137327A TWI533866B (zh) 2009-10-29 2010-10-29 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎抗腫瘤用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW099137327A TWI533866B (zh) 2009-10-29 2010-10-29 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎抗腫瘤用途

Country Status (31)

Country Link
US (8) US8927592B2 (https=)
EP (1) EP2493466B1 (https=)
JP (2) JP5566466B2 (https=)
KR (1) KR101712231B1 (https=)
CN (1) CN102770131A (https=)
AR (1) AR078824A1 (https=)
AU (4) AU2010310986A1 (https=)
BR (1) BR112012011457A2 (https=)
CA (1) CA2779009A1 (https=)
CR (1) CR20120204A (https=)
DK (1) DK2493466T3 (https=)
EA (1) EA024186B1 (https=)
EC (1) ECSP12011836A (https=)
ES (1) ES2862340T3 (https=)
GT (1) GT201200123A (https=)
IL (3) IL219443A0 (https=)
MA (1) MA33767B1 (https=)
MX (1) MX336339B (https=)
MY (1) MY164086A (https=)
NI (1) NI201200071A (https=)
PE (1) PE20121429A1 (https=)
PH (1) PH12012500848A1 (https=)
PL (1) PL2493466T3 (https=)
PT (1) PT2493466T (https=)
SG (1) SG10201810928SA (https=)
SV (1) SV2012004192A (https=)
TN (1) TN2012000188A1 (https=)
TW (2) TWI654975B (https=)
UY (1) UY32987A (https=)
WO (1) WO2011051894A1 (https=)
ZA (1) ZA201203123B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12453712B2 (en) 2009-10-29 2025-10-28 Sanofi Mature Ip Antitumoral use of cabazitaxel

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
CN103764637A (zh) * 2011-04-12 2014-04-30 普拉斯化学品有限公司 卡巴他赛的固态形式及其制备方法
CN102503913B (zh) * 2011-10-20 2014-03-26 江苏红豆杉生物科技股份有限公司 直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
EP2791122B1 (en) 2011-12-13 2019-01-23 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
US9403785B2 (en) * 2012-01-03 2016-08-02 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
WO2014022237A1 (en) * 2012-07-31 2014-02-06 Yung Shin Pharm. Ind. Co., Ltd. Amorphous cabazitaxel
TW201438714A (zh) * 2013-03-04 2014-10-16 Aventis Pharma Sa 卡巴他賽（ｃａｂａｚｉｔａｘｅｌ）及其治療轉移性前列腺癌之用途
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
JP6841772B2 (ja) * 2015-02-17 2021-03-10 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 前立腺癌の処置におけるカバジタキセルの使用
EP3093014A1 (en) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
WO2018047074A1 (en) 2016-09-07 2018-03-15 Cadila Healthcare Limited Sterile injectable compositions comprising drug micelles
US10195214B2 (en) * 2017-03-01 2019-02-05 Corcept Therapeutics, Inc. Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
WO2018187786A1 (en) * 2017-04-07 2018-10-11 La Jolla Institute For Allergy And Immunology Unipotent neutrophil progenitor cells, methods of preparation, and uses thereof
US20250017891A1 (en) * 2023-07-04 2025-01-16 Twi Pharmaceuticals, Inc. Pharmaceutical composition comprising cabazitaxel prodrug-cyclodextrin inclusion complex, and applications thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1849311A (zh) * 2003-09-19 2006-10-18 安万特医药股份有限公司 二甲氧基多西他赛丙酮化物及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5005588A (en) 1989-10-13 1991-04-09 David Rubin Method for increasing tumor sensitivity to chemotherapy
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
ZA94128B (en) 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
FR2732340B1 (fr) 1995-03-27 1997-04-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
FR2745814B1 (fr) 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
US6346543B1 (en) 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
KR20010079665A (ko) 1998-08-20 2001-08-22 추후제출 탁소이드 유도체의 신규 용도
US6403634B1 (en) 1999-01-13 2002-06-11 Aventis Pharma S.A. Use of taxoid derivatives
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
DK1493556T3 (da) 2003-07-02 2005-12-05 Scheuten Glasgroep Bv Fremgangsmåde til fremstilling af brandbeskyttelsesglas
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CN102747140A (zh) 2004-12-08 2012-10-24 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
EP1700596A1 (en) 2005-03-09 2006-09-13 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2177630A1 (en) 2008-10-02 2010-04-21 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
CA2756072A1 (en) 2009-03-30 2010-10-14 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
AU2010295646B2 (en) 2009-09-15 2016-02-11 Ellipses Pharma Limited Treatment of cancer
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
ES2862340T3 (es) * 2009-10-29 2021-10-07 Sanofi Mature Ip Nuevo uso antitumoral de cabazitaxel
US8686165B2 (en) 2009-11-04 2014-04-01 Emcure Pharmaceuticals Limited Process for preparation of taxane derivatives
CN102781237A (zh) 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
WO2011124669A1 (en) 2010-04-08 2011-10-13 Institut Gustave Roussy Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2011130317A2 (en) 2010-04-13 2011-10-20 Amplyx Pharmaceuticals Inc. Therapeutic agents having reduced toxicity
US20110287038A1 (en) 2010-04-16 2011-11-24 Kevin Slawin Method for treating solid tumors
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1849311A (zh) * 2003-09-19 2006-10-18 安万特医药股份有限公司 二甲氧基多西他赛丙酮化物及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FDA Approval for Cabazitaxel，NATIONAL CANCER INSTITUTE，公開日2010年06月17日 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12453712B2 (en) 2009-10-29 2025-10-28 Sanofi Mature Ip Antitumoral use of cabazitaxel

Also Published As

Publication number Publication date
MX336339B (es) 2016-01-14
SG10201810928SA (en) 2019-01-30
KR20120093986A (ko) 2012-08-23
IL250254A0 (en) 2017-03-30
JP6182510B2 (ja) 2017-08-16
PE20121429A1 (es) 2012-11-06
ES2862340T3 (es) 2021-10-07
US20200155497A1 (en) 2020-05-21
AU2016200598A1 (en) 2016-02-25
TN2012000188A1 (en) 2013-12-12
AU2010310986A1 (en) 2012-06-14
UY32987A (es) 2011-05-31
DK2493466T3 (da) 2021-04-26
KR101712231B1 (ko) 2017-03-03
US20210169843A1 (en) 2021-06-10
EP2493466A1 (en) 2012-09-05
PL2493466T3 (pl) 2021-11-15
GT201200123A (es) 2013-11-07
PT2493466T (pt) 2021-03-29
AU2017232227A1 (en) 2017-10-12
EP2493466B1 (en) 2021-03-10
US20190151278A1 (en) 2019-05-23
MY164086A (en) 2017-11-30
TWI533866B (zh) 2016-05-21
AU2017232227B2 (en) 2019-06-06
CA2779009A1 (en) 2011-05-05
IL219443A0 (en) 2012-06-28
AR078824A1 (es) 2011-12-07
US10583110B2 (en) 2020-03-10
EA024186B1 (ru) 2016-08-31
EA201270606A1 (ru) 2013-01-30
MX2012005030A (es) 2012-12-05
BR112012011457A2 (pt) 2016-05-03
JP2014196323A (ja) 2014-10-16
JP2013509394A (ja) 2013-03-14
IL267583A (en) 2019-08-29
US20240139146A1 (en) 2024-05-02
TW201611831A (en) 2016-04-01
TW201127374A (en) 2011-08-16
ECSP12011836A (es) 2012-07-31
MA33767B1 (fr) 2012-11-01
US20180125810A1 (en) 2018-05-10
CR20120204A (es) 2012-07-04
CN102770131A (zh) 2012-11-07
NI201200071A (es) 2012-08-20
WO2011051894A1 (en) 2011-05-05
SV2012004192A (es) 2012-08-23
US20150104411A1 (en) 2015-04-16
PH12012500848A1 (en) 2016-02-08
US20150118182A1 (en) 2015-04-30
AU2019203514A1 (en) 2019-06-06
ZA201203123B (en) 2013-06-26
US12453712B2 (en) 2025-10-28
US8927592B2 (en) 2015-01-06
US10716777B2 (en) 2020-07-21
JP5566466B2 (ja) 2014-08-06
US20120301425A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
TWI654975B (zh) 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之新穎抗腫瘤用途
EP3808345A1 (en) Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
EP3294285B1 (en) Cabazitaxel and its use for treating cancer
AU2015200149B2 (en) Novel antitumoral use of cabazitaxel
HK1173071B (en) Novel antitumoral use of cabazitaxel
HK1173071A (en) Novel antitumoral use of cabazitaxel
CA2708489A1 (en) Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
UA110606C2 (uk) Нове протипухлинне застосування кабазитакселу